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Abstract
Background: Systems that are used by different organisations to grade the quality of evidence and
the strength of recommendations vary. They have different strengths and weaknesses. The GRADE
Working Group has developed an approach that addresses key shortcomings in these systems. The
aim of this study was to pilot test and further develop the GRADE approach to grading evidence
and recommendations.
Methods: A GRADE evidence profile consists of two tables: a quality assessment and a summary
of findings. Twelve evidence profiles were used in this pilot study. Each evidence profile was made
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BMC Health Services Research 2005, 5:25 http://www.biomedcentral.com/1472-6963/5/25based on information available in a systematic review. Seventeen people were given instructions
and independently graded the level of evidence and strength of recommendation for each of the 12
evidence profiles. For each example judgements were collected, summarised and discussed in the
group with the aim of improving the proposed grading system. Kappas were calculated as a measure
of chance-corrected agreement for the quality of evidence for each outcome for each of the twelve
evidence profiles. The seventeen judges were also asked about the ease of understanding and the
sensibility of the approach. All of the judgements were recorded and disagreements discussed.
Results: There was a varied amount of agreement on the quality of evidence for the outcomes
relating to each of the twelve questions (kappa coefficients for agreement beyond chance ranged
from 0 to 0.82). However, there was fair agreement about the relative importance of each
outcome. There was poor agreement about the balance of benefits and harms and
recommendations. Most of the disagreements were easily resolved through discussion. In general
we found the GRADE approach to be clear, understandable and sensible. Some modifications were
made in the approach and it was agreed that more information was needed in the evidence profiles.
Conclusion: Judgements about evidence and recommendations are complex. Some subjectivity,
especially regarding recommendations, is unavoidable. We believe our system for guiding these
complex judgements appropriately balances the need for simplicity with the need for full and
transparent consideration of all important issues.
Background
Reviewers and users of reviews draw conclusions about
the overall quality of the evidence that is reviewed. Simi-
larly, people making recommendations and users of those
recommendations draw conclusions about the strength of
the recommendations that are made. Systematic
approaches to doing this can help protect against errors by
both doers and users, and can facilitate critical appraisal
and communication of the conclusions that are made.
The GRADE Working Group began as an informal collab-
oration of people with an interest in addressing shortcom-
ings in systems for grading evidence and
recommendations. We report elsewhere a critical
appraisal of six prominent systems for grading evidence
and recommendations [1]. Based on this critical appraisal
and a series of discussions, we reached agreement on the
key attributes of a system that would address the major
shortcomings that we identified. Based on the critical
assessment of existing approaches, the agreement we had
reached about the key elements that should be included in
an approach for grading the level of evidence and strength
of recommendations and our previous experiences we put
together a suggestion for a grading system. We then
applied the suggested system to a series of examples and
discussed and revised the system based on this experience
and the consideration of other examples. Examples were
selected to challenge our thinking. All of the examples
used in this pilot study were questions about interven-
tions. We describe here the pilot study of this system.
The aims of the pilot study were to test whether the
approach is sensible relative to diverse examples of evi-
dence and recommendations, and to agree on necessary
changes to the approach, decision rules, and changes in
how the evidence profiles used in the pilot study were
constructed. The revised approach is described elsewhere
[16].
Methods
Seventeen people independently judged the quality of evi-
dence, the balance between benefits and harms, and the
formulation of a recommendation for 12 examples. The
17 judges all had experience using other approaches to
grade evidence and recommendations.
Evidence profiles
For each example we prepared an evidence profile. Each
evidence profile was made based on information availa-
ble in a systematic review and consists of two tables, one
for quality assessment of the available information and
one table that presents a summary of the findings (Table
1 and Table 2). For the purpose of testing our grading
approach in this pilot study we made the assumption that
the systematic reviews that we used were all well con-
ducted. The examples we used and presented here were
selected to test our new approach, not with an intention
of making actual recommendations for a specific setting
based on up-to-date systematic reviews. The quality
assessment table was designed such that the quality of
each outcome was evaluated separately. For each out-
come, the table contained information regarding the
number of studies that had reported the outcome, infor-
mation about the study design (RCTs or observational
studies) and the quality of the studies that reported on
that outcome (was there any limitations in the design orPage 2 of 12
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assessment table was information about the consistency
of the results across studies for each outcome and infor-
mation regarding directness of the study population, out-
come measure, intervention and comparison. The
summary of findings table was also designed such that
each outcome was presented separately. For each outcome
information are presented about both the experimental
and the control group patients, for dichotomous out-
comes the number of events and the total number of par-
ticipants, and for continuous outcomes means (standard
deviation) and the number of patients were presented.
Also included in the summary of findings table is infor-
mation about the effect, relative effect (95% confidence
interval) and absolute effect for each outcome.
Instructions and a form for recording each judgement
were included with each example [see Additional file 1].
The judges were instructed to apply the approach without
second guessing the information presented in the evi-
dence profile or the approach. They were asked to note
problems that they encountered and judgements that did
not make sense to them when they adhered to the
approach as instructed.
Table 1: Example of an evidence profile quality assessment given to the evaluators for them to grade in the pilot study. Example 
question: Should depressed patients in primary care be treated with SSRIs rather than tricyclics?
Outcome: Depression severity (measured with Hamilton Depression Rating Scale)
Studies Design Quality Consistency Directness
8 trials Citalopram
38 trials Fluoxetine
25 trials Fluvoxamine
2 trials Nefazodone
18 trials Paroxetine
4 trials Sertaline
4 trials Velafaxine
RCTs No serious flaws No important 
inconsistency
Some uncertainty about 
relevance (outcome 
measure)
Outcome: Transient side effects (drop-out from 6 week treatment)
8 trials Citalopram
50 trials Fluoxetine
27 trials Fluvoxamine
4 trials Nefazodone
23 trials Paroxetine
6 trials Sertaline
5 trials Velafaxine
RCTs No serious flaws No important 
inconsistency
Some uncertainty about 
relevance (outcome 
measure)
Outcome: Poisoning fatalities
Office for National 
Statistics (British)
Observational data 
(national statistics)
Serious flaw, population based
Reporting bias
Only one study Direct
Table 2: Example of an evidence profile summary of findings given to the evaluators for them to grade in the pilot study. Example 
question: Should depressed patients in primary care be treated with SSRIs rather than tricyclics?
Outcome SSRI tricyclics Effect Quality Relative 
importance
Relative (95% CI) NNT/NNH
Depression Severity 5044 patients 4510 patients WMD 0.034 (-0.007 to 0.075) No difference
Transient side effects 1948/7032 (28%) 2072/6334 (33%) RRR 13% (5% to 20%) 20
Poisoning fatalities* 1/100,000 per year 
of treatment
58/100,000 per year 
of treatment
RRR 98% 1754
* Uncertainty about baseline risk: Fatality data may be influenced by which pills are given to whom, and it is uncertain if changing antidepressant 
would deter suicide attemptsPage 3 of 12
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The 12 examples were selected to include a variety of
health care interventions, types of evidence and types of
recommendations. The questions that were posed in the
12 examples were:
• Should depressed patients in primary care be treated
with SSRIs or tricyclics? [2]
• Should patients with atrial fibrillation be treated with
warfarin or aspirin for prevention of stroke? [3]
• Should patients with pain believed to be due to degen-
erative arthritis be treated with non-steroidal anti-inflam-
matory drugs (NSAIDs) or paracetamol? [4]
• Should patients who have had a myocardial infarction
be given antiplatelet therapy to reduce all cause mortality?
[5]
• Should patients who have had a myocardial infarction
be offered exercise rehabilitation? [5]
• Should patients with deep venous thrombosis be treated
with Low Molecular Weight Heparin (LMWH) or IV
unfractionated heparin for prevention of pulmonary
embolism? [6]
• Should antibiotics be used to treat acute maxillary
sinusitis? [7]
• Should BCG vaccine be used to prevent tuberculosis? [8]
• Should surgical discectomy be recommended for
patients with sciatica due to lumbar disc prolapse? [9]
• Should community water fluoridation be used to reduce
dental caries? [10,11]
• Should distribution of child safety seats and education
programs be used to increase correct use of child safety
seats? [12]
• Should hormone replacement therapy be given to pre-
vent cardiovascular heart disease in healthy post meno-
pausal women? [13]
For each example each person made judgements about;
• the quality of evidence for each outcome, scored as high,
intermediate, low, or very low;
• the relative importance of each outcome, scored as criti-
cal to the decision (7–9), important but not critical to the
decision (4–6), or not important to the decision (1–3);
• the overall quality of all the critical outcomes, scored as
high, intermediate, low, or very low;
• the balance between benefits and harms, scored as net
benefit, trade offs, uncertain net benefit, or not net bene-
fit; and
• the recommendation, scored as do it, probably do it,
toss up, probably don't do it, or don't do it.
For each example the judgements made by all 17 people
were collected and summarised as illustrated in Table 3.
Disagreements were discussed at a meeting attended by 15
of the 17 judges. Because of a lack of time, the last two
examples were discussed at another meeting attended by
six of the 17 judges, but all 17 raters provided judgements
for all of the 12 examples. For each example the kappa
agreement was calculated [14] for the 17 graders across
the four levels for the quality of evidence across outcomes
for each example (number of outcomes per example range
from two to seven), across all outcomes (46) and for the
judgements about overall quality of the evidence (12).
Sensibility and understandability
After grading all 12 examples, the judges were asked 16
questions regarding the sensibility and understandability
of the approach. Each question consisted of a statement
and five response options: strongly disagree, disagree, not
sure, agree, and strongly agree. Eleven people completed
this questionnaire. The questionnaire was adapted from
Feinstein [15] and the 16 statements were:
1. The approach is applicable to different types of inter-
ventions, including drugs, surgery, counselling, and com-
munity-based interventions.
2. The approach is clear and simple to apply
3. The information that is needed is generally available.
4. Subjective decisions are generally not needed.
5. All of the components included in each of the five types
of judgements should be included
6. There are not important components that are missing
for any of the five types of judgements.
7. The ways in which the components are aggregated for
each of the five types of judgements are clear and simple.
8. The ways in which the included components are aggre-
gated are appropriate for each of the five types of
judgements.Page 4 of 12
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different grades for each of the five types of judgements.
10. The approach successfully discriminates between dif-
ferent grades of evidence.
11. The approach successfully discriminates between dif-
ferent grades of recommendations.
12. The overall quality of evidence is clear and
understandable.
13. The balance between the benefits and harms is clear
and understandable.
14. The recommendation is clear and understandable.
15. The way in which the overall quality of evidence was
graded is better than other ways of doing this with which
I am familiar.
16. The way in which the recommendation was graded is
better than other ways of doing this with which I am
familiar.
Results
Quality of evidence for each outcome
The quality of evidence for each outcome as assessed by
the 17 graders are shown in Table 4. Much of the disagree-
ment was due to lacking information in the evidence
summaries that we prepared based on the information
available in the chosen examples. We agreed that the evi-
dence summaries should include footnotes explaining the
basis for judgements about study quality, consistency and
directness. We also agreed that it was necessary to include
information about baseline risk and the setting as part of
the background information since different assumptions
about these factors also explained some of the disagree-
ment. It was possible to reach a consensus about the qual-
ity of evidence for most outcomes when we discussed our
judgements. Of the 48 outcomes that were included
across the 12 examples, we were not able to reach a con-
sensus regarding five. The lack of consensus resulted from
disagreement about whether there was sparse data for
three outcomes and because of insufficient information
for two outcomes.
We found that in addition to study design, quality, con-
sistency and directness, other quality criteria also influ-
enced judgements about evidence. These additional
criteria were sparse data, strong associations, publication
bias, dose response, and situations where all plausible
Table 3: Summary of the judgements made by the 17 evaluators for Example 1 of the pilot study. Should depressed patients in primary 
care be treated with SSRIs rather than tricyclics?
Rater Quality of 
outcome
Relative 
importance 
of outcome
Overall 
quality
Balance benefits vs 
harm
Recommendation
Depressio
n severity
Transient 
side effects
Poisining 
fatalities
Depression 
severity
Transient 
side effects
Poisining 
fatalities
1 H H Vl 7 9 9 H or Vl Uncertain net benefit Don't do it
2 M M Vl 9 6 7 Vl Net benefit Probably do it
3 H H M 8 7 9 H Uncertain net benefit Toss up
4 H H L 6 5 6
5 M M M 9 6 8 M Net benefit Do it
6 M M Vl 9 6 9 Vl Net benefit Do it
7 M M L 8 7 8 L Net benefit Do it
8 H H Vl 9 5 3 H Net benefit Probably do it
9 M M L 9 6 8 L Net benefit Probably do it
10 M M L 9 7 8 L Net benefit Probably do it
11 H H L 8 5 7 L Trade offs Probably do it
12 H H L 8 5 7 L Trade offs Probably do it
13 M H M 9 7 9 M Net benefit Do it
14 M M L 9 9 5 OR 9 M Net benefit Probably do it
15 M M Vl 9 6 8 Vl Uncertain net benefit Toss up
16 M M Vl 9 5 9 Vl Not net benefit Don't do it
17 M M M 9 9 9 M Net benefit Toss upPage 5 of 12
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fidence in the direction of the effect. Concequently, the
consistency with which we considered these additional
issues were affected and disagreements regarding the qual-
ity of evidence for each outcome were reduced.
Relative importance of each outcome
Specification of outcomes in the question that each exam-
ple addressed resulted in some confusion regarding the
relative importance of each outcome and the overall qual-
ity of evidence across outcomes. We therefore agreed that
outcomes should not be included in the questions and
Table 4: Results, summary of the judgements made by the 17 evaluators of the quality for each of the outcomes presented in the 12 
examples in the pilot study.
Outcome High Moderate Low Very low Consensus Comments
Depression severity 6/17 10/17 - - Moderate
Transient side effects 7/17 10/17 - - High Changed to little uncertainty
Poisoning fatalities - 4/17 7/17 6/17 Moderate Upgraded for very strong association
Stroke 15/17 2/17 - - High
Extracranial hemorrage 16/16 - - - High
All cause mortality 12/17 5/17 - - - Agreed to remove this outcome
Pain at rest 16/17 1/17 - - High
Pain ay motion 15/17 2/17 - - Moderate Uncertainty about directness of outcome measure
Mobility 3/17 14/17 - - Moderate
Quality of life 1/17 11/17 5/17 - Moderate
Dropout due to side effects 14/17 3/17 - - High
Serious gi complications - 3/17 8/17 6/17 - Need more information before consensus
All cause mortality 2/17 15/17 - - Moderate
Non-fatal stroke 17/17 - - - High
Non-fatal MI 17/17 - - - High
Death 13/17 4/17 - - High
Non-fatal MI 11/16 5/16 - - High
All cause death 12/17 5/17 - - Moderate If reporting bias, otherwise high
Major bleeding 15/17 2/17 - - High
Recurrent thromboembolism 6/17 11/17 - - High
Clinical cure - 13/17 4/17 - Moderate
Dropout due to side effects - 10/17 7/17 - Moderate
Relapse 2/17 11/17 4/17 - Moderate
Tuberculosis 2/17 10/17 5/17 - Moderate
TB death 8/17 8/17 1/17 - High
TB meningitis 1/17 4/17 12/17 - Moderate Strong association
Serious adverse events 1/12 - - 11/12 - No data, outcome removed
Condition unchanged 5/17 19/17 2/17 - - No consensus regarding sparse data
Poor outcome- surgeon rated 9/17 8/17 - - - Need bias information before consensus
2nd procedure needed 9/17 8/17 - - Moderate
No success – objective rater 5/17 10/17 2/17 - - No consensus regarding sparse data
Risks & side effects 1/15 2/15 2/15 10/15 - No data, outcome removed
Dental caries – start - - 8/17 9/17 Very low
Dental caries – stop - - 5/17 12/17 Very low
Dental florosis - 1/17 3/17 13/17 Very low
Bone fracture - 1/17 3/17 13/17 Very low
Cancer mortality - 1/17 2/17 14/17 Very low
All injuries - 1/17 12/17 4/17 Very low Question changed
Correct use early 8/17 5/17 4/17 - High Question changed
Correct use follow up 2/17 8/17 6/17 1/17 High Question changed
Possession of seat 7/17 6/17 3/17 - High Question changed
CHD 11/13 2/13 - - High
Breast cancer 11/13 2/13 - - High
Stroke 11/13 2/13 - - High
Colorectal cancer 11/13 2/13 - - High
Endometrial cancer 11/13 2/13 - - High
Hip fracture 11/13 2/13 - - HighPage 6 of 12
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was good agreement about the relative importance of the
48 outcomes that were considered. We reached a consen-
sus about the relative importance of all but two of the out-
comes. This was due to uncertainty and true disagreement
about the importance of these two outcomes, dental
fluorosis and bone fractures, in relation to the question
about water fluoridation.
Overall quality of important outcomes
There was a lack of agreement about the overall quality of
evidence across the critical outcomes for each question
(Table 5). This poor agreement reflected an accumulation
of disagreements about the quality of evidence and
importance of the individual outcomes that were consid-
ered for each question. In addition, we found that it did
not make sense to downgrade the overall quality of evi-
dence because of lower quality evidence for one of several
critical outcomes when all of the outcomes showed effect
in the same direction. We therefore agreed that the overall
quality of evidence should be based on the higher quality
evidence, rather than the lowest quality of evidence, when
all of the results are in favour of the same option.
The kappa statistics for each question are shown in Table
6. The number of outcomes per example range from two
to seven and the kappa ranged from 0 to 0.82. In some
instances, the agreement among the graders was slightly
worse than by chance as indicated by the negative kappa
values seen in Table 6. The kappa across the 46 outcomes
included in the calculation was 0.395 (SE 0.008). Kappa
for agreement beyond chance for the 12 final judgements
about the quality of evidence was 0.270 (SE 0.015).
Balance between benefits and harms
The graders assessments about the balance between bene-
fits and harms are shown in Table 7. There is visibly a poor
agreement, this can, in part, be explained by the accumu-
lation of all the previous differences in grading of the
quality and importance of the evidence. Some of the
judges made assumptions or considered information that
was not included in the evidence profiles. When we
discussed these judgements, we reached a consensus
about the balance between benefits and harms for all but
three questions. For one question we found we needed
more information. For the second judgement we disa-
greed about the importance of two of the outcomes. For
the third judgement we disagreed about the relative values
we attached to the benefits and the harms.
Recommendation
The graders individual considerations about the recom-
mendations are shown in Table 8. During the discussion,
Table 5: Results, summary of the judgements made by the 17 evaluators of the overall quality in the 12 examples in the pilot study
Example High Moderate Low Very low Consensus Comments
1 2/15 4/15 5/15 4/15 Moderate
2 12/17 5/17 - - High
3 1/17 6/17 5/17 5/17 Need more information before consensus
4 4/17 13/17 - - High Based on the new rule
5 12/16 4/16 - - High
6 7/17 10/17 - - High Based on new rule
7 - 11/17 6/17 - Moderate
8 - 6/17 3/17 8/17 High Based on new rule
9 2/16 3/16 5/16 6/16 High/Moderate depending if there are fatal flaws
10 - 1/17 4/17 12/17 Very low
11 1/17 3/17 8/17 5/17 High Changed question
12 11/13 2/13 - - High
Table 6: Results, kappa agreement among the evaluators for 
each of the 12 examples in the pilot study
Example No of outcomes P Kappa (SE)
1 3 0.436 0.149 0.031
2 3 0.769 0.075 0.053
3 6 0.643 0.441 0.024
4 3 0.926 0.823 0.050
5 2 0.608 -0.044 0.065
6 3 0.618 0.163 0.050
7 3 0.520 -0.028 0.044
8 3 0.451 0.146 0.036
9 4 0.441 -0.022 0.037
10 5 0.579 0.005 0.034
11 4 0.377 0.112 0.027
12 7 0.718 -0.083 0.043Page 7 of 12
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nine examples where we agreed on the balance between
benefits and harms. We found that first agreeing on the
balance between the benefits and harms clarified our
judgements about recommendations and facilitated a
consensus. There was not a one-to-one correspondence
between our judgements about trade-offs and our
judgements about recommendations, because the latter
took into account additional considerations.
Sensibility and understandability
Eleven raters provided feedback on the sensibility and
understandability of the GRADE system for grading evi-
dence and formulating recommendations. Nine of the 11
respondents agreed or strongly agreed that the judge-
ments about the overall quality of evidence were clear and
understandable, and that the judgements about the
balance between benefits and harms were clear and
understandable using the GRADE approach. Everyone
agreed or strongly agreed that the judgements about
recommendations were clear and understandable. Eight
of the judges agreed or strongly agreed that the GRADE
approach to judging the overall quality of evidence was
better than other grading systems with which they were
familiar. Two disagreed and one was not sure. Eight also
agreed that the GRADE approach to formulating
recommendations was better than approaches with which
the raters were familiar. Three raters were not sure about
whether the GRADE approach was superior to other
approaches of formulating recomendations.
Nine of the 11 respondents agreed or strongly agreed that
the GRADE approach was applicable to different types of
interventions, and that the approach was clear and simple
to apply. Five judges disagreed that the information that is
needed is generally available, two were not sure and four
Table 7: Results, summary of the judgements made by the 17 evaluators about the balance between benefits and harms for each of the 
12 examples in the pilot study
Example Net benefit Trade offs Uncertain net benefits Not net benefits Consensus
1 10/16 2/16 3/16 1/16 Net benefit
2 11/16 4/16 1/16 - Net benefit
3 2/17 8/17 7/17 - Need more information
4 15/16 - 1/16 - Net benefit
5 13/17 - 4/17 - Net benefit
6 13/17 2/17 2/17 - Net benefit
7 4/17 3/17 9/17 1/17 Uncertain net benefits
8 7/16 - 9/16 - Net benefit
9 2/16 8/16 6/16 - Uncertain benefit/trade offs
10 2/17 4/17 10/17 1/17 No consensus
11 12/17 - 5/17 - Net benefit
12 - 2/13 1/13 10/17 No consensus
Table 8: Results, summary of the recommendations made the 17 evaluators for each of the 12 examples in the pilot study
Example Do it Probably do it Toss up Probably don't do it Don't do it Consensus
1 4/16 7/16 3/16 - 2/16 Probably do it
2 6/16 8/16 2/16 - - Do it
3 - 6/15 7/15 2/15 - Need more information
4 13/15 2/15 - - - Do it
5 11/16 5/16 - - - Do it
6 11/17 5/17 1/17 - - Do it
7 1/17 7/17 2/17 6/17 1/17 Probably do it
8 2/15 7/15 4/15 2/15 - Do it
9 1/17 4/17 8/17 4/17 - Probably don't do it/Tossup
10 - 2/17 6/17 7/17 2/17 No consensus
11 7/17 8/17 2/17 - - Do it
12 - - - 4/13 9/13 No consensusPage 8 of 12
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greed that subjective decisions were generally not needed,
four were not sure and one agreed. Ten of the eleven
judges agreed or strongly agreed that all the components
included in each of the four types of judgements should
be included; one judge was not sure. Five of the judges
were unsure if there were not important components that
were missing from any of the four types of judgements,
one disagreed and three agreed or strongly agreed. Eight
judges agreed or strongly agreed that the ways in which
the components were aggregated for each of the four types
of judgements were clear and simple; three were unsure.
Seven judges agreed or strongly agreed that the ways in
which the included components were aggregated were
appropriate for each of the four types of judgements, two
were unsure and two disagree. Ten of the eleven judges
agreed or strongly agreed that the categories were suffi-
cient to discriminate between different grades for each of
the four types of judgements; one disagreed. All the eleven
judges agreed or strongly agreed that the GRADE
approach successfully discriminated between different
quality of evidence, and between different grades of
recommendations.
Discussion
This pilot study of the GRADE approach to grading the
quality of evidence and strength of recommendations
helped to identify problems with the approach and ena-
bled us to address these. We found that it was possible to
resolve most of the disagreements we had when making
judgements independently and there was agreement that
this approach warrants further development and
evaluation.
Many of the disagreements were a direct result of a lack of
information. We concluded that there is a need for
detailed additional information in evidence profiles, and
have modified the evidence profiles accordingly. When
we have found an empirical basis or compelling argu-
ments, we have also provided precise definitions. For
example, we have agreed on a basis for defining strong
and very strong associations. However, in many cases we
continue to rely on judgement. We have addressed this by
always including the rationale for such judgements in
footnotes attached to the evidence profile.
The evidence profiles used in the pilot study were based
on systematic reviews. [2-13] Much of the information we
found lacking was missing in these original systematic
reviews, particularly information about harms and side
effects. It was outside of the scope of this study to system-
atically collect this information. However, systematic
reviews of evidence of harms, as well as benefits, are essen-
tial for guidelines development panels. If reviews, such as
Cochrane reviews, are going to meet the needs of guide-
line development panels, and others making decisions
about health care, it is essential that evidence of adverse
effects is systematically included in these.
An important benefit of the approach to grading evidence
and recommendations that we used in this study is that it
clarifies the source of true disagreements, as well as help-
ing to resolve disagreements through discussing each type
of judgement sequentially. Judgements about the relative
importance of different outcomes and about trade-offs, as
well as about the quality of evidence, are made explicitly,
rather than implicitly. This facilitates discussion and clar-
ification of these judgements. It may be helpful to guide-
line panels and others to use this approach before making
decisions and recommendations.
The most common source of disagreement that we
encountered was differences in what we consider to be
sparse data. We have not reached a consensus on a defini-
tion of sparse data, but have acknowledged that we have
different thresholds and now recognize this when we
make judgements about the quality of evidence [16].
We have as a result of this pilot study been able to make
considerable improvements to our system for grading the
quality of evidence and strength of recommendations.
The evidence profiles used in the pilot study have been
modified and now include information that was missing
and was found to be an important source of disagreement,
as illustrated in Table 9 and Table 10 and the criteria used
for grading the quality of evidence for each important out-
come have been modified as summarised in Table 11.
Guideline generation includes judgement. Individual,
residual judgements will impact on the agreement we
measured in this study. Thus, lower kappa values are
expected. Further refinement of the GRADE system and
additional instructions will improve agreement.
Judgements about confidence in evidence and recommen-
dations are complex. The GRADE system represents our
current thinking about how to reduce errors and improve
communication of these complex judgements. Ongoing
developments include:
• Exploring the extent to which the same system should be
applied to public health and health policy decisions as
well as clinical decisions
• Developing guidance for when and how costs (resource
utilisation) should be considered
• Developing guidance for judgements regarding sparse
dataPage 9 of 12
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BMC Health Services Research 2005, 5:25 http://www.biomedcentral.com/1472-6963/5/25Table 9: Example of a modified GRADE evidence profile quality assessment. Table 9 and 10 is what Table 1 and 2 became when 
including the improvements made based on the pilot study experience. Question: Should depressed patients be treated with SSRIs 
rather than tricyclics? Setting: Primary care Patients: Moderately depressed adult patients Reference: North of England Evidence 
Based Guideline Development Project. Evidence based clinical practice guideline: the choice of antidepressants for depression in 
primary care. Newcastle upon Tyne: Centre for Health Services Research, 1997.
Outcome: Depression severity (measured with Hamilton Depression Rating Scale after 4 to 12 weeks)
Studies Design Quality Consistency Directness SD SA RB DR PC
8 trials Citalopram
38 trials Fluoxetine
25 trials Fluvoxamine
2 trials Nefazodone
18 trials Paroxetine
4 trials Sertaline
4 trials Velafaxine
RCTs No serious 
limitations
No important 
inconsistency
Some uncertainty about directness 
(outcome measure)*
No No No No No
Outcome: Transient side effects resulting in discontinuation of treatment
8 trials Citalopram
50 trials Fluoxetine
27 trials Fluvoxamine
4 trials Nefazodone
23 trials Paroxetine
6 trials Sertaline
5 trials Velafaxine
RCTs No serious 
limitations
No important 
inconsistency
Direct No No No No No
Outcome: Poisoning fatalities
Office for National 
Statistics (British)
Observational 
data
Serious 
limitation**
Only one study Direct No ++ No No No
*There was uncertainty about the directness of the outcome measure because of the short duration of the trials.
**It is possible that people at lower risk were more likely to have been given SSRI's and it is uncertain if changing antidepressant would have 
deterred suicide attempts.
SD = Sparse data (Yes or No)
SA = Strong association (No, + = strong, ++ = very strong)
RB = Reporting bias (Yes or No)
DR = Dose response (Yes or No)
PC = All plausible confounders would have reduced the effect (Yes or No)
CI = confidence interval
WMD = weighted mean difference
RRR = relative risk reduction
Table 10: Example of a modified GRADE evidence profile summary of findings. Table 9 and 10 is what Table 1 and 2 became when 
including the improvements made based on the pilot study experience
Outcome SSRI Tricyclics Effect Quality Importance
Relative (95% CI) Absolute
Depression severity 5044 patients 4510 patients WMD 0.034 (-0.007 to 0.075) No difference Moderate Critical
Transient side effects 1948/7032 (28%) 2072/6334 (33%) RRR 13% (5% to 20%) 5 per 100 High Critical
Poisoning fatalities*** 1/100,000 per year 
of treatment
58/100,000 per 
year of treatment
RRR 98% (97% to 99%) 6 per 10,000 Moderate Critical
***There is uncertainty about the baseline risk for poisoning fatalities.Page 10 of 12
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BMC Health Services Research 2005, 5:25 http://www.biomedcentral.com/1472-6963/5/25• Adapting the approach to accommodate recommenda-
tions about diagnostic tests when these are based on evi-
dence of test accuracy
• Incorporating considerations about equity
• Preparing tools to support the application of the GRADE
system
Plans for further development include studies of the relia-
bility and sensibility of this approach and a study
comparing alternative ways of presenting these judge-
ments [17]. We invite other organisations responsible for
systematic reviews of the effects of healthcare or practice
guidelines to work with us to further develop and evaluate
the system described here.
Conclusion
Based on the results of this pilot study we have been able
to considerably improve our system for grading the qual-
ity of evidence and strength of recommendation [16].
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Table 11: Modified GRADE quality assessment criteria
Quality of evidence Study design Lower if * Higher if *
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Directness:
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-2-Major uncertainty
-1-Sparse data
-1-High probability of Reporting bias
Strong association:
+1-Strong, no plausible confounders, consistent and 
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+2-Very strong, no major threats to validity and 
direct evidence***
+1-Evidence of a Dose response gradient
+1-All plausible confounders would have reduced 
the effect
Moderate Quasi-randomised trial
Low Observational study
Very low Any other evidence
* 1 = move up or down one grade (for example from high to moderate)
2 = move up or down two grades (for example from high to low)
The highest possible score is High (4) and the lowest possible score is Very low (1). Thus, for example, randomised trials with a strong association 
would not move up a grade.
** A relative risk of >2 (< 0.5), based on consistent evidence from two or more observational studies, with no plausible confounders
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